Bookcover of Current and Emerging First-line Therapies in Renal Clear-cell Cancer
Booktitle:

Current and Emerging First-line Therapies in Renal Clear-cell Cancer

Rapidly evolving landscape in renal cell cancer

LAP LAMBERT Academic Publishing (2019-11-01 )

Books loader

Omni badge eligible for voucher
ISBN-13:

978-620-0-46311-1

ISBN-10:
6200463115
EAN:
9786200463111
Book language:
English
Blurb/Shorttext:
Currently, 7 targeted agents and the combination of nivolumab/ipilimumab have been approved as first-line therapy for mccRCC. Sunitinib and pazopanib are the most effective first-line options, especially in favorable- and indermediate-risk patients. Nivolumab/ipilimumab seem to be the preferred first-line therapy in poor-risk patients, although cabozantinib, temsirolimus, sunitinib and pazopanib are also recommended. HD IL-2 remains a reasonable first-line treatment option in selected, favorable-risk younger patients with good performance status. The combination of ICI/VEGF-TKI is currently underway. Combinations of pembrolizumab/axitinib, avelumab/axitinib, atezolizumab/bevacizumab and pembrolizumab/lenvatinib seem to introduce the mccRCC therapy in a new auspicious era.
Publishing house:
LAP LAMBERT Academic Publishing
Website:
https://www.lap-publishing.com/
By (author) :
Theodoros Tegos, Athanasios Raptis, George Dimitriadis
Number of pages:
52
Published on:
2019-11-01
Stock:
Available
Category:
Medicine
Price:
26.90 €
Keywords:
targeted therapy, metastatic renal cell carcinoma, immune checkpoint inhibitors, emerging first-line systemic therapies

Books loader

Newsletter

Adyen::amex Adyen::mc Adyen::visa Adyen::cup Adyen::unionpay Paypal Wire Transfer

  0 products in the shopping cart
Edit cart
Loading frontend
LOADING